Perceptual characteristics of parkinsonian speech: A comparison of the pharmacological effects of levodopa across speech and non-speech motor systems

NeuroRehabilitation

Volumn 24, Issue 2, 2009, Pages 131-144

  Plowman Prine, E K ^a,b   Okun, M S ^a   Sapienza, C M ^a,b   Shrivastav, R ^a,b   Fernandez, H H ^a   Foote, K D ^c   Ellis, C ^d   Rodriguez, A D ^a,b   Burkhead, L M ^e   Rosenbek, J C ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Medical University   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Hypokinetic dysarthria; Intelligibility; Levodopa; Parkinson's disease; Perceptual assessment of speech

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; BREATHING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; MOTOR SYSTEM; PARKINSON DISEASE; PHONATION; PITCH; SPEECH; SPEECH ANALYSIS; SPEECH ARTICULATION; SPEECH DISORDER; SPEECH RATE; STRESS; UNIFIED PARKINSON DISEASE RATING SCALE; VOICE; COMPARATIVE STUDY; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; SOUND DETECTION; SPEECH INTELLIGIBILITY;

AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SOUND SPECTROGRAPHY; SPEECH; SPEECH ACOUSTICS; SPEECH INTELLIGIBILITY; VOICE QUALITY;

EID: 66149126979     PISSN: 10538135     EISSN: None     Source Type: Journal    
DOI: 10.3233/NRE-2009-0462     Document Type: Article

References (93)

1. H. Ackermann, J. Konczak and I. Hertrich, The temporal control of repetitive articulatory movements in Parkinson's disease, Brain Lang 56(2) (1997), 312-319.
2. H. Ackermann and W. Ziegler, Articulatory deficits in parkin-sonian dysarthria: an acoustic analysis, J Neurol Neurosurg Psychiatry 54(12) (1991), 1093-1098.
3. S. Adams, M. Jog, T. Eadie, A. Dykstra, G. Gauthier and J. Vercher, Jaw and finger movements during visual and auditory motor tracking in Parkinson Disease, Journal of Medical Speech Pathology 4 (2004), 125-130.
4. J. Adelman, R. Hoel and M. Lassman, The effect of L-Dopa treatment on speech in Parkinson's Disease, Neurology 20 (1970), 410-411.
5. G.E. Alexander, Basal ganglia-thalamocortical circuits: their role in control of movements, J Clin Neurophysiol 11(4) (1994), 420-431.
6. G.E. Alexander and M.D. Crutcher, Functional architeture of basal ganglia circuits: neural substrates of parallel processing, Trends Neurosci 13(7) (1990), 266-271.
7. G.E. Alexander, M.D. Crutcher and M.R. DeLong, Basal ganglia- thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions, Prog Brain Res 85 (1990), 119-146.
8. G.E. Alexander, M.R. DeLong, and P.L. Strick, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Annu Rev Neurosci 9 (1986), 357-381.
9. J.M. Anderson, J.D. Hughes, L.J. Rothi, G.P. Crucian and K.M. Heilman, Developmental stuttering and Parkinson's disease: the effects of levodopa treatment, J Neurol Neurosurg Psychiatry 66(6) (1999), 776-778.
10. T. Benke, C. Hohenstein, W. Poewe and B. Butterworth, Repetitive speech phenomena in Parkinson's disease, J Neurol Neurosurg Psychiatry 69(3) (2000), 319-324.
11. G.Broggi, A. Franzini, C. Marras, L.Romito and A. Albanese, Surgery of Parkinson's disease: inclusion criteria and follow-up, Neurol Sci 24(Suppl 1) (2003), S38-S40.
12. D.B. Calne, G.M. Stern, A.S. Spiers and D.R. Laurence, L-dopa in idiopathic parkinsonism, Lancet 2(7628) (1969), 973-976.
13. G.J. Canter, Speech characteristicsofpatientswith Parkinson's disease II: physiological support for speech, J Speech Hear Res 30 (1965), 44-49.
14. G.J. Canter, Speech Characteristics of Patients with Parkinson's Disease 3: articulation, diadochokinesis, and over-all speech adequacy, J Speech Hear Disord 30 (1965), 217-224.
15. J. Cohen, Statistical Power Annalysis For Behavioral Science, (2nd ed.), Lawerence Objective Association, Hillsdale, NJ, 1998.
16. N.P. Connor and J.H. Abbs, Task-dependent variations in parkinsonian motor impairments, Brain 114 (Pt 1A) (1991), 321-332.
17. E.M. Critchley, Speech disorders of Parkinsonism: a review, J Neurol Neurosurg Psychiatry 44(9) (1981), 751-758.
18. N. Daniels, J. Oates, D. Phyland, A. Feiglin and A. Hughes, Vocal characteristics in response to levodopa in Parkinson's Disease, Movement Disorders 11(Suppl 1) (1996), 117.
19. F.L. Darley, A.E. Aronson and J.R. Brown, Differential diagnostic patterns of dysarthria, J Speech Hear Res 12(2) (1969), 246-269.
20. F.L. Darley, A.E. Aronson and J.R. Brown, Clusters of deviant speech dimensions in the dysarthrias, J Speech Hear Res 12(3) (1969), 462-496.
21. F.L. Darley, A.E. Aronson and J.R. Brown, Motor Speech Disorders, W.B. Saunders, Philadelphia, 1975.
22. M.S. De Bodt, H.M. Hernandez-Diaz and P.H. Van De Heyn-ing, Intelligibility as a linear combination of dimensions in dysarthric speech, J Commun Disord 35(3) (2002), 283-292.
23. M. De Letter, P. Santens, M. De Bodt, P. Boon and J. Van Borsel, Levodopa-induced alterations in speech rate in advanced Parkinson's disease, Acta Neurol Belg 106(1) (2006), 19-22.
24. M. De Letter, P. Santens and J. Van Borsel, The effects of levodopa on tongue strength and endurance in patients with Parkinson's disease, Acta Neurol Belg 103(1) (2003), 35-38.
25. M.R. Delong, A.P. Georgopoulos, M.D. Crutcher, S.J. Mitchell, R.T. Richardson and G.E. Alexander, Functional organization of the basal ganglia: contributions of single-cell recording studies, Ciba Found Symp 107 (1984), 64-82.
26. C. Dromey, R. Kumar, A.E. Lang and A.M. Lozano, An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice, Mov Disord 15(6) (2000), 1132-1138.
27. A. Farrell, D. Theodoros, E. Ward, B. Hall and P. Silburn, Effects of neurosurgical management of Parkinson's disease on speech characteristics and oromotor function, J Speech Lang Hear Res 48(1) (2005), 5-20.
28. M. Ferrarin, M. Rizzone, L. Lopiano, M. Recalcati and A. Pedotti, Effects of subthalamic nucleus stimulation and L-dopa in trunk kinematics of patients with Parkinson's disease, Gait Posture 19(2) (2004), 164-171.
29. K. Forrest, G. Weismer and G.S. Turner, Kinematic, acoustic, and perceptual analyses of connected speech produced by parkinsonian and normal geriatric adults, J Acoust Soc Am 85(6) (1989), 2608-2622.
30. C. Fox, C. Morrison and L.O. Ramig, Current perspectives on the Lee Silverman Voice Treatment (LSVT), Am J Speech Lang Pathol 11 (2002), 111-123.
31. S. Gallena, P.J. Smith, T. Zeffiro and C.L. Ludlow, Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease, J Speech Lang Hear Res 44(6) (2001), 1284-1299.
32. I. Gath and E. Yair, Analysis of vocal tract parameters in parkinsonian speech, J Acoust Soc Am 84(5) (1988), 1628-1634.
33. M. Gentil, C.L. Tournier, S. Perrin and P. Pollak, Effects of levodopa on finger and orofacial movements in Parkinson's disease, Progress in Neuro-Psychopharmacology and Biological Psychiatry 22 (1998), 1261-1274.
34. M. Gentil, C.L. Tournier, P. Pollak and A.L. Benabid, Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease, Eur Neurol 42(3) (1999), 136-140.
35. A. Goberman, C. Coelho and M. Robb, Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states, J Commun Disord 35(3) (2002), 217-239.
36. A. Goberman, C. Coelho and M. Robb, Prosodic characteristics of Parkinsonian speech: The effect of Levodopa-based medication, Journal of Medical Speech Pathology 13(1) (2005), 51-68.
37. A.M. Goberman, Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease, Med Sci Monit 11(3) (2005), CR109-CR116.
38. R.B. Godwin-Austen, E.B. Tomlinson, C.C. Frears and H.W. Kok, Effects of L-dopa in Parkinson's disease, Lancet 2(7613) (1969), 165-168.
39. D.G. Hanson, B.R. Gerratt and P.H. Ward, Cinegraphic observations of laryngeal function in Parkinson's disease, Laryngoscope 94(3) (1984), 348-353.
40. L. Hartelius and P. Svensson, Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey, Folia Phoniatr Logop 46(1) (1994), 9-17.
41. H. Hirose, Pathophysiology of motor speech disorders (dysarthria), Folia Phoniatr (Basel) 38(2-4) (1986), 61-88.
42. A.K. Ho,R.Iansek, C. Marigliani, J.L. Bradshaw andS. Gates, Speech impairment in a large sample of patients with Parkinson's disease, Behav Neurol 11(3) (1998), 131-137.
43. M.M. Hoehn and M.D. Yahr, Parkinsonism: onset, progression and mortality, Neurology 17(5) (1967), 427-442.
44. A.J. Hughes, S.E. Daniel, L. Kilford and A.J. Lees, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, Journal of Neuro-surgery and Psychiatry 55(3) (1992), 181-184.
45. J.L. Izquierdo-Alonso, F.j. Jimenez-Jimenez, F. Cabrera-Valdivia and M. Mansilla-Lesmes, Airway dysfunction in patients with Parkinson Disease, Lung 172(1) (1994), 47-55.
46. J. Jiang, E. Lin, J. Wang and D.G. Hanson, Glottographic measures before and after levodopa treatment in Parkinson's disease, Laryngoscope 109(8) (1999), 1287-1294.
47. R.D. Kent, J.R. Duffy, A. Slama, J.F. Kent and A. Clift, Clin-icoanatomic studies in dysarthria: review, critique, and directions for research, J Speech Lang Hear Res 44(3) (2001), 535-551.
48. J. King, L.O. Ramig, J. Lemke and Y. Horii, Parkinson's disease: longitudinal changes in acoustic parameters of phona-tion, Journal of Medical Speech Pathology 2 (1994), 29-42.
49. K. Kompoliti, Q.E. Wang, C.G. Goetz, S. Leurgans and R. Raman, Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease, Neurology 54(2) (2000), 458-462.
50. K.K. Larson, L.O. Ramig and R.C. Scherer, Acoustic and glottographic voice analysis during drug-related fluctations in Parkinson's disease, Journal of Medical Speech Pathology 2 (1994), 227-239.
51. R. Leanderson, B.A. Meyerson and A. Persson, Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory function, J Neurol Neurosurg Psychiatry 34(6) (1971), 679-681.
52. S.B. Leder, Adult onset of stuttering as a presenting sign in a parkinsonian-like syndrome: a case report, J Commun Disord 29(6) (1996), 471-477; quiz 477-478.
53. C. Lee, M. Grossman, J. Morris, M.B. Stern and H.I. Hurtig, Attentional resource and processing speed limitations during sentence processing in Parkinson's disease, Brain Lang 85(3) (2003), 347-356.
54. M. Liotti and L.O. Ramig, Functional reorganization of speech-motor function in Parkinson's disease following LSVT: A PET study, Neurology 60 (2003), 432-440.
55. J. Logemann and H. Fisher, Vocal tract control in Parkinson's disease: phonetic feature analysis of misarticulations, J Speech Hear Disord 46(4) (1981), 348-352.
56. J.A. Logemann, H.B. Fisher, B. Boshes and E.R. Blonsky, Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients, J Speech Hear Disord 43(1) (1978), 47-57.
57. E.D. Louis, L. Winfield, S. Fahn and B. Ford, Speech dys-fluency exacerbated by levodopa in Parkinson's disease, Mov Disord 16(3) (2001), 562-565.
58. M. Maschke, C.M. Gomez, P.J. Tuite and J. Konczak, Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia, Brain 126(Pt 10) (2003), 2312-2322.
59. E.J. Metter and W.R. Hanson, Clinical and acoustical variability in hypokinetic dysarthria, J Commun Disord 19(5) (1986), 347-366.
60. C. Moore and R. Scudder, Coordination of Jaw Muscle Activity in Parkinsonian Movement: Description and Response to Traditional Treatment, Recent Advances in Clinical Dysarthria, (College-Hill Press, Boston, MA, 1989).
61. R. Moretti, P. Torre, R.M. Antonello, L. Capus, M. Gioulis, S. Zambito Marsala, G. Cazzato and A. Bava, 'Speech initiation hesitation' following subthalamic nucleus stimulation in a patient with Parkinson's disease, Eur Neurol 49(4) (2003), 251-253.
62. P.B. Mueller, Parkinson's disease: motor-speech behavior in a selected group of patients, Folia Phoniatr (Basel) 23(5) (1971), 333-346.
63. B.E. Murdoch, H.J. Chenery, S. Bowler and J.C. Ingram, Respiratory function in Parkinson's subjects exhibiting a perceptible speech deficit: a kinematic and spirometric analysis, J Speech Hear Disord 54(4) (1989), 610-626.
64. K.K. Nakano, H. Zubick and H.R. Tyler, Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility, Neurology 23(8) (1973), 865-870.
65. R. Netsell, B. Daniel and G.G. Celesia, Acceleration and weakness in parkinsonian dysarthria, J Speech Hear Disord 40(2) (1975), 170-178.
66. K.S. Perez, L.O. Ramig, M.E. smith and C. Dromey, The Parkinson larynx: tremor and videostroboscopic findings, J Voice 10(4) (1996), 354-361.
67. S. Pinto, C. Ozsancak, E. Tripoliti, S. Thobois, P. Limousin-Dowsey and P. Auzou, Treatments for dysarthria in Parkinson's disease, Lancet Neurol 3(9) (2004), 547-556.
68. P.C. Poluha, H.L. Teulings and R.H. Brookshire, Handwriting and speech changes across the levodopa cycle in Parkinson's disease, Acta Psychol (Amst) 100(1-2) (1998), 71-84.
69. C.E. Quaglieri and G.G. Celesia, Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients, Eur Neurol 15(1) (1977), 34-39.
70. L.O. Ramig, S. Countryman, L.L. Thompson and Y. Horii, Comparison of two forms of intensive speech treatment for Parkinson disease, J Speech Hear Res 38(6) (1995), 1232-1251.
71. L.O. Ramig, C. Fox and S. Sapir, Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment, Semin Speech Lang 25(2) (2004), 169-180.
72. L.O. Ramig and W.J. Gould, Speech characteristics in Parkinson's disease, Neurologic Consultant 4(1) (1986), 1-6.
73. L.O. Ramig, S. Sapir, S. Countryman, A.A. Pawlas, C. O'Brien, M. Hoehn and L.L. Thompson, Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up, J Neurol Neurosurg Psychiatry 71(4) (2001), 493-498.
74. L.O. Ramig, S. Sapir, C. Fox and S. Countryman, Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls, Mov Disord 16(1) (2001), 79-83.
75. O. Rascol, P. Payoux, F. Ory, J.J. Ferreira, C. Brefel-Courbon and J.L. Montastruc, Limitations of current Parkinson's disease therapy, Ann Neurol 53(Suppl 3) (2003), S3-S12; discussion S12-S15.
76. M. Rousseaux, P. Krystkowiak, O. Kozlowski, C. Ozsancak, S. Blond and A. Destee, Effects of subthalamic nucleus stimulation on parkinsonian dysarthria and speech intelligibility, J Neurol 251(3) (2004), 327-334.
77. J. Sanabria, P.G. Ruiz, R. Gutierrez, F. Marquez, P. Escobar, M. Gentil and C. Cenjor, The effect of levodopa on vocal function in Parkinson's disease, Clin Neuropharmacol 24(2) (2001), 99-102.
78. R. Sandyk and M.J. Brennan, Impairment of somatosensory feedback control of the tongue in Parkinson's disease: effect of L-Dopa therapy, S Afr J Commun Disord 29 (1982), 49-54.
79. L. Sapir, L.O. Ramig, S. Hoyt, C. Countryman, C. O'Brien and M. Hoehn, Speech loudness and quality 12 months after intensive voice treatment (LSVT) for Parkinson's disease: a comparison with an alternative speech treatment, Folia Phoniatr Logop 54(6) (2002), 296-303.
80. P.L. Schiffman, A "saw-tooth" pattern in Parkinson's disease, Chest 87(1) (1985), 124-126.
81. G.M. Schulz, The effects of speech therapy and pharmacological treatments on voice and speech in Parkinson s disease: a review of the literature, Curr Med Chem 9(14) (2002), 1359-1366.
82. G.M. Schulz and M.K. Grant, Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's disease: a review of the literature, J Commun Disord 33(1) (2000), 59-88.
83. K.C. Simmons and R. Mayo, The use of the Mayo Clinic system for differential diagnosis of dysarthria, J Commun Disord 30(2) (1997), 117-131; quiz 131-112.
84. M.E. Smith, L.O. Ramig, C. Dromey, K.S. Perez and R. Samandari, Intensive voice treatment in Parkinson disease: laryngostroboscopic findings, J Voice 9(4) (1995), 453-459.
85. N.P. Solomon and T.J. Hixon, Speech breathing in Parkinson's disease, J Speech Hear Res 36(2) (1993), 294-310.
86. P.A. Starr, J.L. Vitek, M. Delong and R.A. Bakay, Magnetic resonance imaging-based stereotactic localization of the globus pallidus and subthalamic nucleus, Neurosurgery 44(2) (1999), 303-313.
87. P. Svensson, C. Henningson and S. Karlsson, Speech motor control in Parkinson's disease: a comparison between a clinical assessment protocol and a quantitative analysis of mandibular movements, Folia Phoniatr (Basel) 45(4) (1993), 157-164.
88. D.G. Theodoros, E.C. Ward, B.E. Murdoch, P. Silburn and J. Lethlean, The impact of pallidotomy on motor speech function in Parkinson's disease, Journal of Medical Speech Pathology 8(4) (2000), 315-322.
89. W.G. Vincken, S.G. Gauthier, R.E. Dollfuss, R.E. Hanson, C.M. Darauay and M.G. Cosio, Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation, N Engl J Med 311(7) (1984), 438-442.
90. J. Volkmann, V. Sturm, P. Weiss, J. Kappler, J. Voges, A. Koulousakis, R. Lehrke, H. Hefter and H.J. Freund, Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease, Ann Neurol 44(6) (1998), 953-961.
91. E. Wang, Verhagen Metman L, R.A. Bakay, J. Arzbaecher and B. Bernard, The effect of unilateral electrostimulation of the subthalamic nucleus on respiratory/phonatory subsytems of speech producation in Parkinson's disease: a preliminary report, Clin Linguist Phon 17(4-5) (2003), 283-289.
92. V.I. Wolfe, J.S. Garvin, M. Bacon and W. Waldrop, Speech changes in Parkinson's disease during treatment with L-dopa, J Commun Disord 8(3) (1975), 271-279.
93. K.M. Yorkston and D.R. Beukelman, A comparison of techniques for measuring intelligibility of dysarthric speech, J Commun Disord 11(6) (1978), 499-512.